Introduction
EBD Group began with a straightforward mission: to connect biotech CEOs with pharma executives seeking partnerships on innovative products. However, the demand for collaboration quickly exceeded expectations, driving the rapid growth of EBD events alongside the life sciences industry—now a global innovation powerhouse valued at over $500 billion. While the biotech business model continues to rely on collaboration, its importance has only deepened as drug development grows increasingly complex. In response, we have remained steadfast in EBD's core mission: connecting biotech partners to advance life sciences innovation. As EBD enters its third decade, we are proud to continue this tradition by bringing the global life sciences community together at BIO-Europe this past November in Stockholm and this coming March at BIO-Europe Spring in Milan. We welcome you to experience at first-hand the collaborative community that continues to drive biotech innovation.
